Vicadrostat by Boehringer Ingelheim International for Chronic Kidney Disease (Chronic Renal Failure): Likelihood of Approval

Vicadrostat is under clinical development by Boehringer Ingelheim International and currently in Phase III for Chronic Kidney Disease (Chronic Renal Failure).

Cybin Reports Second Quarter Financial Results and Recent Business Highlights | Psychedelic Invest

–Announced unprecedented positive Phase 2 interim data for CYB003, its proprietary deuterated psilocybin analog, in major depressive disorder – – Announced closing of a unit

November 15, 2023

Meridian Bioscience announces FDA clearance for innovative Curian® Shiga Toxin Assay

Meridian Bioscience, Inc., a leading global provider of diagnostic testing solutions and life science raw materials.

September 18, 2023

Study reveals link between traumatic experiences and endometriosis risk

The study finds a connection between trauma and endometriosis, suggesting that addressing psychological factors could improve diagnosis and treatment outcomes.

February 10, 2025

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.